

PSYCHEMEDICS CORP  
Form 10-Q  
November 12, 2010

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 10-Q

Quarterly report pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934

For the quarterly period ended September 30, 2010

or

Transition report pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934

for the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission file number: 1-13738

PSYCHEMEDICS CORPORATION  
(Exact Name of Registrant as Specified in its Charter)

Delaware  
(State or Other Jurisdiction of  
Incorporation or Organization)

58-1701987  
(I.R.S. Employer  
Identification No.)

125 Nagog Park  
Acton, MA  
(Address of Principal Executive Offices)

01720  
(Zip Code)

Registrant's telephone number including area code: (978) 206-8220

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer (as defined in Rule 12b-2 of the Securities Exchange Act of 1934).

Large accelerated filer  Accelerated filer  Non-accelerated filer  Smaller Reporting Company

Edgar Filing: PSYCHEMEDICS CORP - Form 10-Q

(Do not check if smaller reporting  
Company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Securities Exchange Act of 1934).

Yes  No

The number of shares of Common Stock of the Registrant, par value \$0.005 per share, outstanding at November 12, 2010 was 5,212,536.

---

PSYCHEMEDICS CORPORATION  
FORM 10-Q FOR THE QUARTER ENDED SEPTEMBER 30, 2010

INDEX

|                                                                                                       | Page |
|-------------------------------------------------------------------------------------------------------|------|
| <b>PART I - FINANCIAL INFORMATION</b>                                                                 |      |
| <b>Item 1 - Financial Statements (Unaudited)</b>                                                      |      |
| Condensed Balance Sheets as of September 30, 2010 and December 31, 2009                               | 3    |
| Condensed Statements of Income for the Three and Nine Months Ended September 30, 2010 and 2009        | 4    |
| Condensed Statements of Cash Flows for the Nine Months Ended September 30, 2010 and 2009              | 5    |
| Notes to Condensed Financial Statements                                                               | 6    |
| <b>Item 2 - Management's Discussion and Analysis of Financial Condition and Results of Operations</b> |      |
| Overview                                                                                              | 12   |
| Results of Operations                                                                                 | 13   |
| Liquidity and Capital Resources                                                                       | 14   |
| Critical Accounting Policies and Estimates                                                            | 16   |
| <b>Item 3 - Quantitative and Qualitative Disclosures About Market Risk</b>                            | 18   |
| <b>Item 4 - Controls and Procedures</b>                                                               | 18   |
| <b>PART II - OTHER INFORMATION</b>                                                                    |      |
| <b>Item 1A - Risk Factors</b>                                                                         | 19   |
| <b>Item 2 - Unregistered Sales of Equity Securities and Use of Proceeds</b>                           | 19   |
| <b>Item 6 - Exhibits</b>                                                                              | 19   |
| <b>Signatures</b>                                                                                     | 20   |
| <b>Exhibit Index</b>                                                                                  | 21   |

PSYCHEMEDICS CORPORATION  
CONDENSED BALANCE SHEETS  
(UNAUDITED)

|                                                                                                                                    | September 30,<br>2010 | December 31,<br>2009 |
|------------------------------------------------------------------------------------------------------------------------------------|-----------------------|----------------------|
| <b>ASSETS</b>                                                                                                                      |                       |                      |
| Current Assets:                                                                                                                    |                       |                      |
| Cash and cash equivalents                                                                                                          | \$ 2,872,960          | \$ 4,840,367         |
| Short-term investments                                                                                                             | 2,017,407             | 1,006,436            |
| Accounts receivable, net of allowance for doubtful accounts of \$86,400 in 2010 and \$134,282 in 2009                              | 4,335,593             | 3,016,084            |
| Prepaid expenses                                                                                                                   | 697,226               | 573,191              |
| Other current assets                                                                                                               | 168,681               | 90,242               |
| Deferred tax assets                                                                                                                | 304,994               | 253,221              |
| <b>Total Current Assets</b>                                                                                                        | <b>10,396,861</b>     | <b>9,779,541</b>     |
| Fixed Assets:                                                                                                                      |                       |                      |
| Equipment & leasehold improvements                                                                                                 | 11,320,800            | 10,912,906           |
| Less accumulated depreciation                                                                                                      | (10,585,459)          | (10,381,599)         |
| <b>Net Fixed Assets</b>                                                                                                            | <b>735,341</b>        | <b>531,307</b>       |
| Deferred tax assets, long term                                                                                                     | 204,764               | 204,764              |
| Other assets                                                                                                                       | 84,927                | 86,814               |
| <b>Total Assets</b>                                                                                                                | <b>\$ 11,421,893</b>  | <b>\$ 10,602,426</b> |
| <b>LIABILITIES AND SHAREHOLDERS' EQUITY</b>                                                                                        |                       |                      |
| Current Liabilities:                                                                                                               |                       |                      |
| Accounts payable                                                                                                                   | \$ 361,389            | \$ 180,784           |
| Accrued expenses                                                                                                                   | 743,040               | 759,067              |
| Accrued income taxes                                                                                                               | 413,699               | 331,831              |
| Deferred revenues                                                                                                                  | 16,515                | 36,360               |
| <b>Total Current Liabilities</b>                                                                                                   | <b>1,534,643</b>      | <b>1,308,042</b>     |
| Commitments and Contingencies (Note 9)                                                                                             |                       |                      |
| Shareholders' Equity:                                                                                                              |                       |                      |
| Preferred-stock, \$0.005 par value, 872,521 shares authorized, no shares issued or outstanding                                     | -                     | -                    |
| Common stock, \$0.005 par value, 50,000,000 shares authorized, 5,877,358 shares issued in 2010 and 5,861,872 shares issued in 2009 | 29,387                | 29,309               |
| Paid-in capital                                                                                                                    | 27,690,178            | 27,419,359           |
| Less - Treasury stock, at cost, 664,523 shares in 2010 and 2009                                                                    | (10,053,364)          | (10,053,364)         |
| Accumulated deficit                                                                                                                | (7,778,951)           | (8,100,920)          |
| <b>Total Shareholders' Equity</b>                                                                                                  | <b>9,887,250</b>      | <b>9,294,384</b>     |
| <b>Total Liabilities &amp; Shareholders' Equity</b>                                                                                | <b>\$ 11,421,893</b>  | <b>\$ 10,602,426</b> |

See accompanying notes to condensed financial statements



PSYCHEMEDICS CORPORATION  
CONDENSED STATEMENTS OF INCOME  
(UNAUDITED)

|                                                        | 3 Months Ended        |                       | 9 Months Ended        |                       |
|--------------------------------------------------------|-----------------------|-----------------------|-----------------------|-----------------------|
|                                                        | September 30,<br>2010 | September 30,<br>2009 | September 30,<br>2010 | September 30,<br>2009 |
| Revenues                                               | \$ 5,106,262          | \$ 4,669,894          | \$ 14,992,625         | \$ 12,683,654         |
| Cost of revenues                                       | 2,080,214             | 1,779,732             | 6,033,093             | 5,595,740             |
| Gross Profit                                           | 3,026,048             | 2,890,162             | 8,959,532             | 7,087,914             |
| Operating expenses:                                    |                       |                       |                       |                       |
| General & administrative                               | 850,312               | 862,518               | 2,760,195             | 2,784,379             |
| Marketing & selling                                    | 722,815               | 643,139               | 2,098,192             | 2,325,538             |
| Research & development                                 | 116,534               | 111,402               | 364,445               | 353,965               |
| Total operating expenses                               | 1,689,661             | 1,617,059             | 5,222,832             | 5,463,882             |
| Operating income                                       | 1,336,387             | 1,273,103             | 3,736,700             | 1,624,032             |
| Interest income                                        | 4,940                 | 11,576                | 19,422                | 34,166                |
| Net income before provision<br>for income taxes        | 1,341,327             | 1,284,679             | 3,756,122             | 1,658,198             |
| Provision for income taxes                             | 523,959               | 516,373               | 1,559,391             | 676,986               |
| Net income                                             | \$ 817,368            | \$ 768,306            | \$ 2,196,731          | \$ 981,212            |
| Basic net income per share                             | \$ 0.16               | \$ 0.15               | \$ 0.42               | \$ 0.19               |
| Diluted net income per share                           | \$ 0.16               | \$ 0.15               | \$ 0.42               | \$ 0.19               |
| Dividends declared per share                           | \$ 0.12               | \$ 0.12               | \$ 0.36               | \$ 0.41               |
| Weighted average common<br>shares outstanding, basic   | 5,212,835             | 5,178,545             | 5,205,480             | 5,182,504             |
| Weighted average common<br>shares outstanding, diluted | 5,228,378             | 5,184,061             | 5,219,760             | 5,194,118             |

See accompanying notes to condensed financial statements

PSYCHEMEDICS CORPORATION  
CONDENSED STATEMENTS OF CASH FLOWS  
(UNAUDITED)

Nine Months Ended  
September 30,  
2010                      2009

**CASH FLOWS FROM OPERATING ACTIVITIES:**

|                                                                                   |              |            |
|-----------------------------------------------------------------------------------|--------------|------------|
| Net income                                                                        | \$ 2,196,731 | \$ 981,212 |
| Adjustments to reconcile net income to net cash provided by operating activities: |              |            |
| Depreciation and amortization                                                     | 205,747      | 262,435    |
| Stock-based compensation                                                          | 320,158      | 305,473    |
| Deferred income taxes                                                             | (51,773)     | (120,691)  |
| Changes in assets and liabilities                                                 |              |            |
| Accounts receivable                                                               | (1,319,509)  | (411,761)  |
| Prepaid expenses and other current assets                                         | (202,474)    | 381,456    |
| Accounts payable                                                                  | 180,605      | (342,139)  |
| Accrued expenses                                                                  | (16,027)     | (654,146)  |
| Accrued income taxes                                                              | 81,868       | 213,217    |
| Deferred revenue                                                                  | (19,845)     | (109,350)  |
| Net cash provided by operating activities                                         | 1,375,481    | 505,706    |

**CASH FLOWS USED IN INVESTING ACTIVITIES:**

|                                                   |             |             |
|---------------------------------------------------|-------------|-------------|
| Purchases of short-term investments               | (1,010,971) | (1,002,781) |
| Purchases of equipment and leasehold improvements | (407,894)   | (34,423)    |
| Other assets                                      | -           | (12,471)    |
| Net cash used in investing activities             | (1,418,865) | (1,049,675) |

**CASH FLOWS USED IN FINANCING ACTIVITIES:**

|                                                |              |              |
|------------------------------------------------|--------------|--------------|
| Net proceeds from issuance of stock            | (49,261)     |              |
| Acquisition of treasury stock                  | -            | (79,407)     |
| Cash dividends paid                            | (1,874,762)  | (2,390,420)  |
| Net cash used in financing activities          | (1,924,023)  | (2,469,827)  |
| Net decrease in cash                           | (1,967,407)  | (3,013,796)  |
| Cash and Cash Equivalents, beginning of period | 4,840,367    | 6,630,119    |
| Cash and Cash Equivalents, end of period       | \$ 2,872,960 | \$ 3,616,323 |

**Supplemental Disclosures of Cash Flow Information:**

|                            |              |      |
|----------------------------|--------------|------|
| Cash paid for income taxes | \$ 1,525,000 | \$ 0 |
|----------------------------|--------------|------|

See accompanying notes to condensed financial statements





PSYCHEMEDICS CORPORATION  
NOTES TO CONDENSED FINANCIAL STATEMENTS  
(UNAUDITED)

1. Interim Financial Statements

The accompanying unaudited interim financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission for reporting on Form 10-Q. Accordingly, certain information and footnote disclosure required for complete financial statements are not included herein. It is recommended that these financial statements be read in conjunction with the financial statements and related notes of Psychemedics Corporation (“the Company,” “our Company,” “our” or “we”) as reported in the Company’s Annual Report on Form 10-K for the year ended December 31, 2009, filed on March 26, 2010. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of financial position, results of operations, and cash flows at the dates and for the periods presented have been included. The results of operations for the three and nine months ended September 30, 2010 may not be indicative of the results that may be expected for the year ending December 31, 2010, or any other period.

2. Cash, Cash Equivalents & Short-Term Investments

The Company considers all highly liquid investments with original maturities of 90 days or less to be cash equivalents. Cash equivalents consist of cash savings and U.S. government insured certificates of deposit. As of September 30, 2010, all investments were in U.S. government insured certificates of deposit. As of December 31, 2009, \$1.0 million was in U.S. federal government-backed money-market accounts, and \$2.0 million was in government issued certificates of deposit with maturities under 90 days – all of which are classified as cash and cash equivalents.

As of September 30, 2010, the Company had \$2.0 million of CDs with maturities of greater than 13 weeks classified as short-term investments. The Company accounts for investment securities in accordance with the FASB codification topic ASC 320, “Fair Value Debt and Equity Securities,” (ASC 320). Under ASC 320, investments that the Company has positive intent and ability to hold to maturity are classified as held-to-maturity and are reported at amortized cost, which approximates fair market value. The Company intends to hold all the CDs to maturity.

3. Stock-Based Compensation

The Company’s “2006 Equity Incentive Plan” provides for the grant or issuance to officers, directors, employees and consultants of options with terms of up to ten years, restricted stock, issuances of stock bonuses or other stock-based awards, covering up to 250,000 shares of common stock. As of September 30, 2010, 73,950 shares remained available for future grant under the 2006 Equity Incentive Plan.

PSYCHEMEDICS CORPORATION  
NOTES TO CONDENSED FINANCIAL STATEMENTS  
(UNAUDITED)

3. Stock-Based Compensation (continued)

The Company granted stock unit awards (“SUAs”) covering 94,000 shares of common stock on April 7, 2010. The Company did not grant any SUAs in the first nine months of 2009. In the third quarter of 2010, there were 9,850 previously granted SUAs that terminated. There were no previously granted SUAs that terminated during the first nine months of 2009. The fair value of the SUAs was determined by the closing price of the Company’s common stock on the date of grant. The SUAs vest over a period of two years for non-employee board members and four years for employees and are convertible into an equivalent number of shares of the Company’s common stock provided that the director or employee receiving the award remains continuously employed throughout the vesting period. The Company records compensation expense related to the SUAs on a straight-line basis over the vesting term of the SUA. Employees are issued shares upon vesting, net of tax withholdings. No other types of equity-based awards have been granted or issued under the 2006 Equity Incentive Plan.

A summary of activity for SUAs (Stock Unit Awards) under the Company’s 2006 Equity Incentive Plan for the nine months ended September 30, 2010 is as follows:

|                                         | Number of<br>Shares | Aggregate<br>Intrinsic<br>Value(1)<br>(000s) |
|-----------------------------------------|---------------------|----------------------------------------------|
| Unvested, December 31, 2009             | 42,600              |                                              |
| Granted                                 | 94,000              |                                              |
| Forfeited/expired                       | (15,914)            |                                              |
| Converted to common stock               | (15,486)            |                                              |
| Unvested, September 30, 2010            | 105,200             | \$ 978                                       |
| Available for grant, September 30, 2010 | 73,950              |                                              |

(1) The aggregate intrinsic value on this table was calculated based on the closing market value of the Company’s stock on September 30, 2010 (\$9.30).

As of September 30, 2010, the Company also had outstanding an aggregate of 289,371 options to acquire common stock under plans that had previously expired. A summary of stock option activity for the Company’s expired stock option plans for the nine months ended September 30, 2010 is as follows:

## PSYCHEMEDICS CORPORATION

NOTES TO CONDENSED FINANCIAL STATEMENTS  
(UNAUDITED)

## 3. Stock-Based Compensation (continued)

|                                         | Number of<br>Shares | Weighted<br>Average<br>Exercise Price<br>Per Share | Weighted<br>Average<br>Remaining<br>Contractual Life | Aggregate<br>Intrinsic<br>Value (2)<br>(000s) |
|-----------------------------------------|---------------------|----------------------------------------------------|------------------------------------------------------|-----------------------------------------------|
| Outstanding, December 31, 2009          | 336,921             | \$ 14.80                                           |                                                      |                                               |
| Granted                                 | -                   | -                                                  |                                                      |                                               |
| Exercised                               | -                   | -                                                  |                                                      |                                               |
| Terminated/Expired                      | (47,550)            | \$ 19.92                                           |                                                      |                                               |
| Outstanding, September 30, 2010         | 289,371             | \$ 13.96                                           | 3.9 years                                            | \$ -                                          |
| Exercisable, September 30, 2010         | 289,371             | \$ 13.96                                           | 3.9 years                                            | \$ -                                          |
| Available for grant, September 30, 2010 | -                   |                                                    |                                                      |                                               |

(2) The aggregate intrinsic value on this table was calculated based on the amount, if any, by which the closing market value of the Company's stock on the September 30, 2010 (\$9.30) exceeded the exercise price of the underlying options, multiplied by the number of shares subject to each option.

As of September 30, 2010, a total of 468,521 shares of common stock were reserved for issuance under the various stock option and stock-based plans including the previously expired plans. As of September 30, 2010, the unamortized fair value of awards relating to outstanding SUAs and options was \$811 thousand, which is expected to be amortized over a weighted average amortized period of 2.9 years.

## 4. Basic and Diluted Net Income Per Share

Basic net income per share is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per share is computed by dividing net income by the weighted average number of common and dilutive common equivalent shares outstanding during the period. The number of dilutive common equivalent shares outstanding during the period has been determined in accordance with the treasury-stock method. Common equivalent shares consist of common stock issuable upon the exercise of outstanding options and assume the full vesting of all outstanding, unvested SUAs. The Company's unvested SUAs do not have stock dividend rights and, consequently, are not included in share totals.

PSYCHEMEDICS CORPORATION  
NOTES TO CONDENSED FINANCIAL STATEMENTS  
(UNAUDITED)

Basic and diluted weighted average common shares outstanding are as follows:

|                                                               | Three Months Ended    |                       | Nine Months Ended     |                       |
|---------------------------------------------------------------|-----------------------|-----------------------|-----------------------|-----------------------|
|                                                               | September 30,<br>2010 | September 30,<br>2009 | September 30,<br>2010 | September 30,<br>2009 |
|                                                               | (in thousands)        |                       |                       |                       |
| Weighted average common shares                                | 5,213                 | 5,179                 | 5,205                 | 5,183                 |
| Common equivalent shares                                      | 15                    | 5                     | 15                    | 11                    |
| Weighted average common shares outstanding, assuming dilution | 5,228                 | 5,184                 | 5,220                 | 5,194                 |

For the three months ended September 30, 2010 and 2009, options to purchase 280 thousand and 348 thousand common shares, respectively, were outstanding but not included in the diluted weighted average common share calculation as the effect would have been antidilutive. For the nine month period ended September 30, 2010 and 2009, options to purchase 304 thousand and 368 thousand common shares, respectively, were outstanding but not included in the diluted weighted average common share calculation as the effect would have been antidilutive.

#### 5. Revenue Recognition

The Company is in the business of performing drug testing services and reporting the results thereof. The Company's drug testing services include training for collection of samples and storage of positive samples for its customers for an agreed-upon fee per unit tested of samples. The revenues are recognized when the predominant deliverable, drug testing, is provided and reported to the customer.

The Company recognizes revenue under the FASB codification topic ASC 605, "Revenue Recognition," (ASC 605). In accordance with ASC 605, the Company considers testing, training and storage elements as one unit of accounting for revenue recognition purposes, as the training and storage costs are de minimis and do not have stand-alone value to the customer. The Company recognizes revenue as the service is performed and reported to the customer, since the predominant deliverable in each arrangement is the testing of the units.

The Company also provides expert testimony, when and if necessary, to support the results of the tests, which is generally billed separately and recognized as the services are provided.

PSYCHEMEDICS CORPORATION  
NOTES TO CONDENSED FINANCIAL STATEMENTS  
UNAUDITED

Deferred revenue represents payments received in advance of the performance of drug testing procedures, generally in relation to the personal drug testing kits PDT-90. Deferred revenue is recognized as revenue when the underlying test results are delivered. With respect to a portion of these transactions, there may be instances where the customer ultimately does not require performance. Revenue is then recognized when the Company can reasonably, reliably and objectively determine that it is remote that performance will be required for an estimable portion of transactions. The Company recorded \$6 thousand and \$15 thousand of revenue in the results of operations for the three months ended September 30, 2010 and 2009, respectively, related to test kits that were sold for which the Company's obligations to provide service were deemed remote. The Company recorded \$25 thousand and \$117 thousand of revenue in the results of operations for the nine months ended September 30, 2010 and 2009, respectively, related to test kits that were sold for which the Company's obligations to provide service were deemed remote.

At September 30, 2010 and December 31, 2009, the Company had deferred revenue of approximately \$17 thousand and \$36 thousand, respectively, reflecting sales of its personal drug testing service for which the performance of the related test had not yet occurred and future obligations were not deemed remote.

6. Fair Value Measurements

ASC 820, Fair Value Measurements and Disclosures, provides guidance for using fair value to measure assets and liabilities. It also responds to investors' requests for expanded information about the extent to which companies' measure assets and liabilities at fair value, the information used to measure fair value, and the effect of fair value measurements on earnings. ASC 820 applies whenever other standards require (or permit) assets or liabilities to be measured at fair value, and does not expand the use of fair value in any new circumstances.

It establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy prioritizes the inputs in three broad levels as follows:

- Level 1 inputs are unadjusted quoted prices in active markets that are accessible at the measurement date for identical assets and liabilities.
- Level 2 inputs are quoted prices for similar assets and liabilities in markets that are not active or for which all significant inputs are observable, either directly or indirectly.
- Level 3 inputs are prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.

A financial asset's or liability's classification within the hierarchy is determined based on the lowest level of any input that is significant to the fair value measurement.

PSYCHEMEDICS CORPORATION  
NOTES TO CONDENSED FINANCIAL STATEMENTS  
UNAUDITED

The financial assets of the Company measured at fair value on a recurring basis are cash and cash equivalents and short-term investments. The Company's cash and cash equivalents and short-term investments are classified within level 1 of the fair value hierarchy because they are valued using quoted market prices that are accessible at the measurement date for identical assets and liabilities.

7. Subsequent Events

The Company evaluated all events or transactions that occurred after September 30, 2010 up through the time of filing with the SEC our Quarterly Report on Form 10-Q for the period ended September 30, 2010. During this period, the Company did not have any material recognizable subsequent events, except as disclosed herein.

On November 4, 2010, the Company declared a quarterly dividend of \$0.12 per share for a total of \$625 thousand, which will be paid on December 10, 2010 to shareholders of record on November 26, 2010.

8. Recent Accounting Pronouncements

In January 2010, the FASB issued Accounting Standards Update, "Fair Value Measurements and disclosures (ASU 820) – Improving Disclosures about Fair Value Measurements," which provides additional guidance relating to fair value measurement disclosures. Specifically, companies will be required to separately disclose significant transfers into and out of Level 1 and Level 2 measurements in the fair value hierarchy and the reasons for those transfers. For Level 3 fair value measurements, the new guidance requires a gross presentation of activities within the Level 3 roll forward. Additionally, the FASB also clarified existing fair value measurement disclosure requirements relating to the level of disaggregation, inputs, and valuation techniques. This ASU is effective for interim or annual reporting periods beginning after December 15, 2009, except for the detailed Level 3 disclosures, which are effective for interim or annual reporting periods beginning after December 15, 2010. Since ASU 820 only affects disclosure requirements, the adoption of these provisions will have no impact on our financial condition, results of operations, or cash flows.

9. Commitments and Contingencies

The Company is subject to legal proceedings and claims, which arise in the ordinary course of its business. The Company believes that based upon information available to the Company at this time, the expected outcome of these matters would not have a material impact on the Company's results of operations or financial condition.

Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

FACTORS THAT MAY AFFECT FUTURE RESULTS

From time to time, information provided by the Company or statements made by its employees may contain "forward-looking" information which involves risks and uncertainties. In particular, statements contained in this report which are not historical facts (including, but not limited to, the Company's expectations regarding earnings, earnings per share, revenues, operating cash flows, dividends, future business, growth opportunities, new accounts, customer base, test volume, sales and marketing strategy, business strategy, general and administrative expenses, marketing and selling expenses, research and development expenses, anticipated operating results, strategies with respect to governmental agencies and regulations, cost savings, capital expenditures, liquidity of investments and anticipated cash requirements) may be "forward-looking" statements. The Company's actual results may differ from those stated in any "forward-looking" statements. Factors that may cause such differences include, but are not limited to, risks associated with the expansion of the Company's sales and marketing team, employee hiring practices of the Company's principal customers, development of markets for new products and services offered by the Company, the economic health of principal customers of the Company, global credit market volatility, financial and operational risks associated with possible expansion of testing facilities used by the Company, government regulation (including, but not limited to, Food and Drug Administration regulations), competition and general economic conditions. With respect to the continued payment of cash dividends, factors include, but are not limited to, available surplus, cash flow, capital expenditure reserves required, and other factors that the Board of Directors of the Company may take into account.

OVERVIEW

Psychemedics Corporation was incorporated in 1986. The Company is the world's largest provider of hair testing for drugs of abuse, utilizing a patented hair analysis method involving radioimmunoassay technology and confirmation by mass spectrometry to analyze human hair to detect abused substances. The Company's customers include Fortune 500 companies, as well as small to mid-size corporations, schools and governmental entities located primarily in the United States.

Revenue for the third quarter of 2010 was \$5.1 million, an increase of 9% from third quarter 2009 revenue of \$4.7 million. The Company reported net income of \$0.16 per diluted share for the three months ended September 30, 2010, compared to net income of \$0.15 per share in the comparable period in 2009. At September 30, 2010, the Company had \$4.9 million of cash, cash equivalents and short-term investments. The Company distributed \$626 thousand or \$0.12 per share of cash dividends to its shareholders in the three months ended September 30, 2010. The Company has paid fifty-six consecutive quarterly cash dividends.

## RESULTS OF OPERATIONS

Revenues were \$5.1 million for three months ended September 30, 2010 compared to revenues of \$4.7 million for the three months ended September 30, 2009, representing an increase of 9%. The increase in revenues for the three months ended September 30, 2010 was a result of an increase in testing volume from new and existing clients of 5%, while the average revenue per sample increased 4% during the same period due to favorable mix of clients. Revenues for the nine months ended September 30, 2010 were \$15.0 million, representing an increase of 18% in revenues from the comparable period of 2009 of \$12.7 million. The increase was primarily due to an increase in volume, as test samples were up 16% from the three quarters of 2009.

Gross profit increased \$136 thousand to \$3.0 million for the three months ended September 30, 2010, compared to \$2.9 million for the three months ended September 30, 2009. Direct costs grew by \$300 thousand or 17% for the three months ended September 30, 2010 compared to the same period in 2009, mainly due to a greater volume of samples as well as higher salaries in the current year due to salary cuts that were in effect during the comparable period in 2009. The gross profit margin decreased to 59% for the three months ended September 30, 2010 compared to 62% for the comparable period of 2009. Gross profit for the nine months ended September 30, 2010 increased \$1.9 million to \$9.0 million compared to \$7.1 million for the comparable period in 2009. Direct costs increased by \$437 thousand or 8% for the nine months ended September 30, 2010 when compared to the same period in 2009, mostly due to a greater volume in samples as well as higher salaries in the current year due to salary cuts in the second half of 2009. The gross profit margin grew to 60% for the nine month period ended September 30, 2010 from 56% during the same period in 2009 mainly a result of an increase in volume against direct fixed costs.

General and administrative (“G&A”) expenses were \$850 thousand and \$863 thousand for the three months ended September 30, 2010 and 2009, respectively. As a percentage of revenue, G&A expenses were 17% and 18% for the three months ended September 30, 2010 and 2009, respectively. General and administrative expenses were \$2.8 million for both the nine months ended September 30, 2010 and 2009. As a percentage of revenue, G&A expenses were 18% and 22% for the nine months ended September 30, 2010 and 2009, respectively – this decreasing percentage a result of increasing revenue.

Marketing and selling expenses were \$723 thousand for the three months ended September 30, 2010 as compared to \$643 thousand for the three months ended September 30, 2009, an increase of 12%. Total marketing and selling expenses represented 14% of revenue for both the three months ended September 30, 2010 and 2009. The increase in marketing and selling expenses was primarily from the addition of a Vice President of Sales & Marketing, which was vacant in 2009. For the nine months ended September 30, 2010 and 2009, marketing and selling expenses were \$2.1 million, down \$228 thousand from the prior year at \$2.3 million because of lower staffing levels and related expenses. This was offset, in part, by the hiring of a new Vice President of Sales & Marketing in April 2010.

Research and development (“R&D”) expenses for the three months ended September 30, 2010 were \$117 thousand compared to \$111 thousand for the comparable period of 2009, an increase of 5%. R&D expenses represented 2% of revenue in both the third quarter 2010 and 2009. Research and development expenses for the nine months ended September 30, 2010 were \$364 thousand compared to \$354 thousand in the prior year. R&D expenses represented 2% and 3% of revenue for the second quarters 2010 and 2009, respectively.



Interest income for the three months ended September 30, 2010 decreased by \$7 thousand to \$5 thousand when compared to the same period of 2009 in which interest income was \$12 thousand. Interest income represented interest earned on cash, cash equivalents and short-term investments. Interest income for the nine months ended September 30, 2010 decreased \$15 thousand to \$19 thousand as compared to \$34 thousand for the same period in 2009. Interest income represented interest and dividends earned on cash and cash equivalents and short-term investments. Decreasing interest rates on our mix of cash, cash equivalents and short-term investments caused the decrease in interest income for both the three and nine month periods ended September 30, 2010.

Provision for income taxes During the three months ended September 30, 2010 and 2009, the Company recorded tax provisions of \$524 thousand and \$517 thousand, respectively. These provisions represented effective tax rates of 39% and 40% for both the three month periods ended September 30, 2010 and 2009. During the nine months ended September 30, 2010 and September 30, 2009, the Company recorded tax provisions of \$1.6 million and \$677 thousand, respectively. These provisions represented effective tax rates of 42% and 41% for the nine month periods ended September 30, 2010 and 2009, respectively. The Company expects the effective tax rate for the remaining three months of 2010 to be approximately 42%.

### LIQUIDITY AND CAPITAL RESOURCES

At September 30, 2010, the Company had approximately \$4.9 million of cash, cash equivalents and short-term investments. The Company's operating activities provided net cash of \$1.4 million for the nine months ended September 30, 2010. Investing activities used \$1.4 million of cash in the nine month period while financing activities used \$1.9 million of cash during the first nine months of 2010.

Cash provided by operating activities of \$1.4 million reflected net income of \$2.2 million adjusted for depreciation and amortization of \$206 thousand, stock-based compensation of \$320 thousand, and an increase in accounts payable and accrued income tax of \$181 thousand and \$82 thousand, respectively. This was offset by an increase in accounts receivable of \$1.3 million, an increase in other current assets (prepaid expenses, deferred tax assets, and other current assets) of \$254 thousand and a decrease of other current liabilities (accrued expenses and deferred revenues) of \$36 thousand. Cash used in investing activities included equipment and leasehold improvements of \$408 thousand which were purchased during the first three quarters of 2010.

During the nine months ended September 30, 2010, the Company distributed \$1.9 million in cash dividends to its shareholders. In the first three quarters of 2010, the Company did not repurchase any of its shares. The Company did repurchase 17,219 shares during the nine months ended September 30, 2009 for \$79 thousand. In total, 664,523 shares have been repurchased.

Contractual obligations as of September 30, 2010 were as follows:

|                     | Less<br>Than One<br>Year | 1-3 Years | 4-5 years<br>(in thousands) | After 5<br>Years | Total    |
|---------------------|--------------------------|-----------|-----------------------------|------------------|----------|
| Operating leases    | \$ 435                   | \$ 513    | \$ 98                       | \$ -             | \$ 1,046 |
| Purchase commitment | 118                      | -         | -                           | -                | 118      |
|                     | \$ 553                   | \$ 513    | \$ 98                       | \$ -             | \$ 1,164 |

The Company has a supply agreement with a vendor which requires the Company to purchase isotopes used in its drug testing procedures from this sole supplier in exchange for variable annual payments based upon prior year purchases. Purchases amounted to \$353 thousand for the nine months ended September 30, 2010 as compared to \$439 thousand for the comparable period of 2009. The Company expects to purchase approximately \$118 thousand for the remainder of 2010. In exchange for exclusivity, among other things, the supplier has provided the Company with the right to purchase the isotope technology at fair market value under certain conditions, including the failure to meet the Company's purchase commitments. This agreement does not include a fixed termination date; however, it is cancelable upon mutual agreement by the parties or six months after termination notice by the Company of its intent to use a different technology in connection with its drug testing procedures.

At September 30, 2010, the Company's principal sources of liquidity included an aggregate of approximately \$4.9 million of cash, cash equivalents and short-term investments. Management currently believes that such funds, together with cash generated from operations, should be adequate to fund anticipated working capital requirements and capital expenditures for the next 12 months. Depending upon the Company's results of operations and capital needs, the Company may use various financing sources to raise additional funds, although the Company does not have any such plans at this time. At September 30, 2010, the Company had no long-term debt.

## CRITICAL ACCOUNTING POLICIES

Management believes the most critical accounting policies are as follows:

### Revenue Recognition

The Company is in the business of performing drug testing services and reporting the results thereof. The Company's drug testing services include training for collection of samples and storage of positive samples for its customers for an agreed-upon fee per unit tested of samples. The revenues are recognized when the predominant deliverable, drug testing, is provided and reported to the customer.

The Company recognizes revenue under ASC 605, Revenue Recognition, (formerly Emerging Issue Task Force ("EITF") Issue No. 00-21, Revenue Arrangements with Multiple Deliverables). In accordance with ASC 605, the Company considers testing, training and storage elements as one unit of accounting for revenue recognition purposes, as the training and storage costs are de minimis and do not have stand-alone value to the customer. The Company recognizes revenue as the service is performed and reported to the customer, since the predominant deliverable in each arrangement is the testing of the units.

The Company also provides expert testimony, when and if necessary, to support the results of the tests, which is generally billed separately and recognized as the services are provided.

Deferred revenue represents payments received in advance of the performance of drug testing procedures, generally in relation to the personal drug testing kits PDT-90. Deferred revenue is recognized as revenue when the underlying test results are delivered. With respect to a portion of these transactions, there may be instances where the customer ultimately does not require performance. Revenue is then recognized when the Company can reasonably, reliably and objectively determine that it is remote that performance will be required for an estimable portion of transactions. The Company recorded \$6 thousand and \$15 thousand of revenue in the results of operations for the three months ended September 30, 2010 and 2009, respectively, related to test kits that were sold for which the Company's obligations to provide service were deemed remote. For the nine month periods ending September 30, 2010 and 2009 respectively, these figures totaled \$25 thousand and \$117 thousand.

### Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates, including bad debts and income taxes, and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

#### Allowance for Doubtful Accounts

The allowance for doubtful accounts is based on management's assessment of the collectability of its customer accounts. Management reviews its accounts receivable aging for doubtful accounts and specifically identifies accounts that may not be collectible. The Company routinely assesses the financial strength of its customers and, as a consequence, believes that its accounts receivable credit risk exposure is limited. The Company maintains an allowance for potential credit losses but historically has not experienced any significant losses related to individual customers or groups of customers in any particular industry or geographic area. Bad debt expense has been within management's expectations.

#### Income Taxes

The Company accounts for income taxes using the liability method, which requires the Company to recognize a current tax liability or asset for current taxes payable or refundable and a deferred tax liability or asset for the estimated future tax effects of temporary differences between the financial statement and tax reporting bases of assets and liabilities to the extent that they are realizable. Deferred tax expense (benefit) results from the net change in deferred tax assets and liabilities during the year. A deferred tax valuation allowance is required if it is more likely than not that all or a portion of the recorded deferred tax assets will not be realized.

In July 2006, the Financial Accounting Standards Board ("FASB") issued ASC 740, Income Taxes. ASC 740 contains a two-step approach to recognizing and measuring uncertain tax positions (tax contingencies). The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not that the position will be sustained on an audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount which is more than 50% likely of being realized upon ultimate settlement. We consider many factors when evaluating and estimating our tax positions and tax benefits, which may require periodic adjustments and which may not accurately forecast actual outcomes. The Company adopted the provisions of ASC 740, effective January 1, 2007, without material effect in the financial statements.

The Company operates within multiple taxing jurisdictions and could be subject to audit in these jurisdictions. These audits may involve complex issues, which may require an extended period of time to resolve. The Company has provided for its estimated taxes payable in the accompanying financial statements. Interest and penalties related to income tax matters are recognized as a general and administrative expense. The Company did not have any unrecognized tax benefits and did not have any interest or penalties accrued as of September 30, 2010 or December 31, 2009. The Company does not expect the unrecognized tax benefits to change significantly over the next twelve months.

The above listing is not intended to be a comprehensive list of all of the Company's accounting policies. In many cases, the accounting treatment of a particular transaction is specifically dictated by accounting principles generally accepted in the United States, with no need for management's judgment in their application. There are also areas in which management's judgment in selecting any available alternative would not produce a materially different result.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Interest Rate Sensitivity. The Company maintains cash and cash equivalents which consist of cash, money market funds and certificates of deposit with financial institutions. Due to the conservative nature and relatively short duration of our cash, cash equivalents and short-term investments, interest rate risk is mitigated.

Based on our ability to access our cash, cash equivalents and short-term investments, our expected operating cash flows and our other sources of cash; we do not anticipate that any lack of liquidity will materially affect our ability to operate our business.

Item 4. Controls and Procedures

As of the date of this report, our Chief Executive Officer and our Controller performed an evaluation of the effectiveness of the design and operation of the Company's disclosure controls and procedures pursuant to Exchange Act Rule 13a-14. Based upon that evaluation, the Chief Executive Officer and Controller concluded that the Company's disclosure controls and procedures were effective for ensuring that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act of 1934 is recorded, processed, summarized and disclosed within the time periods specified in the SEC's rules and forms, and that its disclosure controls and procedures were also effective to ensure that information required to be disclosed in the reports that it files or submits under the Exchange Act is accumulated and communicated to management, including the Company's principal executive and principal financial officers, to allow timely decisions regarding required disclosure. There were no significant changes in the Company's internal controls over financial reporting or in other factors that could significantly affect these internal controls over financial reporting subsequent to the date of the most recent evaluation.

PART II OTHER INFORMATION

Item 1A. Risk Factors

There have been no material changes in our risk factors from those disclosed in our 2009 Annual Report on Form 10-K.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

There were no purchases of treasury stock in the first three quarters of 2010.

Item 6. Exhibits

See Exhibit Index included in this Report

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Psychemedics Corporation

Date: November 12, 2010

By: /s/ Raymond C. Kubacki, Jr.  
Raymond C. Kubacki, Jr.  
Chairman and Chief Executive Officer  
(principal executive officer)

Date: November 12, 2010

By: /s/ Neil L. Lerner  
Neil L. Lerner  
Vice President and Controller  
(principal accounting officer)

PSYCHEMEDICS CORPORATION  
FORM 10-Q  
September 30, 2010

EXHIBIT INDEX

|      | Page No.                                                                                                                                              |    |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------|----|
| 31.1 | Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002                                                    | 22 |
| 31.2 | Certification of Principal Accounting Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002                                               | 23 |
| 32.1 | Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002      | 24 |
| 32.2 | Certification of Principal Accounting Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | 25 |